![TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration | Nature Neuroscience TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration | Nature Neuroscience](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41593-021-00975-6/MediaObjects/41593_2021_975_Fig1_HTML.png)
TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration | Nature Neuroscience
![Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/d557c858-844a-4623-824b-9e1efe750d5d/gr1.jpg)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet
![Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trials - The Lancet Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trials - The Lancet](https://www.thelancet.com/cms/asset/afc9b13d-4d49-42d1-86d1-f45062bedec1/gr1.jpg)
Balloon catheters versus vaginal prostaglandins for labour induction (CPI Collaborative): an individual participant data meta-analysis of randomised controlled trials - The Lancet
![Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/073b4386-a995-486e-9cc5-f9da92e896f1/gr1.jpg)